Stock Market Reviews

MDGL (Madrigal Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on MDGL (Madrigal Pharmaceuticals, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Madrigal Pharmaceuticals (MDGL) Losses Worsen, Profitability Forecast Sparks Debate on Valuation Narratives
  Madrigal Pharmaceuticals (MDGL) remains in the red, with losses accelerating at a rate of 15.3% per year over the past five years and no improvement in net profit margin. Looking ahead, though, forecasts call for a significant turnaround: revenue is projected to surge by 35.7% per year, easily outpacing the US market average of 10.5%. Earnings are expected to climb at an impressive 67.22% annually, setting Madrigal up for potential profitability within three years, a pace that stands out in...
  Nov 6, 2025 - $MDGL
• Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
  CONSHOHOCKEN, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on November 1, 2025 to 18 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accorda
  Nov 6, 2025 - $MDGL
• Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up
  MDGL's wider Q3 loss fails to deter investors, as soaring Rezdiffra sales drive revenues past estimates and lift the stock.
  Nov 5, 2025 - $MDGL
• Sector Update: Health Care Stocks Advance Late Afternoon
  Health care stocks rose late Wednesday afternoon with the NYSE Health Care Index gaining 0.4% and th
  Nov 5, 2025 - $MDGL
• Soleno slumps despite sales uptick; Madrigal’s MASH drug continues ascent
  Soleno shares fell double digits amid questions about the growth trajectory of its Prader-Willi drug. Elsewhere, a cancer medicine at the center of a $1.9 billion buyout fell short in a key trial.
  Nov 5, 2025 - $MDGL
• Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates
  Madrigal (MDGL) delivered earnings and revenue surprises of -156.57% and +15.30%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 4, 2025 - $MDGL
• Madrigal: Q3 Earnings Snapshot
  WEST CONSHOHOCKEN, Pa. AP) — Madrigal Pharmaceuticals Inc. MDGL) on Tuesday reported a loss of $114.2 million in its third quarter.
  Nov 4, 2025 - $MDGL
• Madrigal Pharmaceuticals Inc (MDGL) Q3 2025 Earnings Call Highlights: Strong Sales Growth and ...
  Madrigal Pharmaceuticals Inc (MDGL) reports a 35% increase in net sales and expands its global presence with the launch of ResDFRA in Germany.
  Nov 4, 2025 - $MDGL
• Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates
  Third-quarter 2025 Rezdiffra™ (resmetirom) net sales of $287.3 millionAs of September 30, 2025, more than 29,500 patients on Rezdiffra Closed global licensing agreement with CSPC Pharma to add oral GLP-1 to pipeline New Orange Book listed patent for Rezdiffra providing protection into 2045 Launched Rezdiffra in Germany following European Commission approval Reports cash, cash equivalents, restricted cash and marketable securities of $1.1 billion as of Sept. 30, 2025Company to host conference cal
  Nov 4, 2025 - $MDGL
• Analysts Estimate electroCore, Inc. (ECOR) to Report a Decline in Earnings: What to Look Out for
  electroCore (ECOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Oct 29, 2025 - $MDGL